Ginkgo Bioworks Holdings (DNA) Assets (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Assets came in at $1.0 billion in Q1 2026, down 20.13% YoY from $1.3 billion in Q1 2025, and down 7.74% on a QoQ basis from $1.1 billion in Q4 2025.
Analysis
Ginkgo Bioworks Holdings (DNA) Assets (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Assets data on file, last reported at $1.0 billion in Q1 2026.
- Quarterly Assets fell 20.13% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 20.13% YoY) and the FY2025 annual result came in at $1.1 billion, down 18.71% from the prior year.
- Assets slipped to $1.0 billion in Q1 2026, from $1.1 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $2.5 billion in Q4 2022 to a low of $1.0 billion in Q1 2026.
- A 5-year average of $1.7 billion and a median of $1.6 billion in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets rose 22.61% — and 2024, when it tumbled 34.56%.
- Tracing DNA's Assets over 5 years: stood at $2.5 billion in 2022, then sank by 34.42% to $1.7 billion in 2023, then declined by 17.29% to $1.4 billion in 2024, then decreased by 18.71% to $1.1 billion in 2025, then fell by 7.74% to $1.0 billion in 2026.
- The last three Assets figures came in at $1.0 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Ginkgo Bioworks Holdings | 428.45 Mn | 343.92 Mn | 18.44 Mn | 990.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 990.05 Mn |
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 1.12 Bn |
| Sep 30, 2025 | 1.19 Bn |
| Jun 30, 2025 | 1.23 Bn |
| Mar 31, 2025 | 1.29 Bn |
| Dec 31, 2024 | 1.38 Bn |
| Sep 30, 2024 | 1.48 Bn |
| Jun 30, 2024 | 1.63 Bn |
| Mar 31, 2024 | 1.58 Bn |
| Dec 31, 2023 | 1.67 Bn |
| Sep 30, 2023 | 2.03 Bn |
| Jun 30, 2023 | 2.29 Bn |
| Mar 31, 2023 | 2.42 Bn |
| Dec 31, 2022 | 2.54 Bn |
| Sep 30, 2022 | 1.87 Bn |
| Jun 30, 2022 | 1.99 Bn |
| Mar 31, 2022 | 2.06 Bn |
| Dec 31, 2021 | 2.07 Bn |
| Sep 30, 2021 | 2.15 Bn |